MCC-950

MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1 [1]. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes [2]. Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations [3]. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model) [3]. Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome [4]. A valuable new tool for exploring the pathophysiology of NLRP3.

References:

1) RE Laliberte et al. J. Biol. Chem. 2003 278:16567

2) RC Coll et al. PLoS One 2011 6(12):e29539

3) RC Coll et al. Nat. Med. 2015 21:248

4) N Kaneko et al. J. Immunol. Methods 2015 426:76"6) Z Li et al. Proc. Natl. Acad. Sci. USA  2013 110:5004